Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibAndreas Hochhaus, H. Kantarjian, Michele Baccarani et al.|Leukemia|2008Cited by 354
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaMarkus Pfirrmann, Bengt Simonsson, Michele Baccarani et al.|Leukemia|2015Cited by 298
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemiaAlberto Álvarez‐Larrán, Carlos Besses, Vicente Vicente et al.|Blood|2010Cited by 233
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia veraAlberto Álvarez‐Larrán, Carles Besses, Arturo Pereira et al.|Blood|2011Cited by 225
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Claire Harrison et al.|Leukemia|2022Cited by 63